Effect of tiered prescription copayments on the use of preferred brand medications

Medical Care

Volumn 41, Issue 3, 2003, Pages 398-406

  Rector, Thomas S ^a   Finch, Michael D ^a   Danzon, Patricia M ^b   Pauly, Mark V ^b   Manda, Bharati S ^a  

^a UNITEDHEALTH GROUP   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Copayments; Drug benefits; Formularies; Managed care

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP;

AGED; ARTICLE; CLASSIFICATION; COST; DRUG ANTAGONISM; ECONOMICS; FEE; FEMALE; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT SATISFACTION; PHARMACOKINETICS; PUBLICATION; REGRESSION ANALYSIS; UNITED STATES;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST SHARING; FEMALE; FORMULARIES; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDEPENDENT PRACTICE ASSOCIATIONS; INSURANCE, PHARMACEUTICAL SERVICES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PRESCRIPTION FEES; PROTON PUMPS; REGRESSION ANALYSIS; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 85047698457     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MLR.0000053022.47132.82     Document Type: Article

References (19)

1. Hibbard JH, Weeks EC Consumerism in health care, prevalence and predictors. Med Care 1987;25:1019-1032.
2. Bearden WO, Mason JB. Consumer-perceived risk and attitudes toward generically prescribed drugs. J Applied Psychol 1978;63:741-746.
3. Lambert ZV, Doering PL, Goldstein E, et al. Predispositions toward generic drug acceptance. J Consumer Res 1980;7:14-23.
4. Sleath B, Roter D, Chewning B, et al. Asking questions about medications, analysis of physician-patient interactions and physician perceptions. Med Care 1999;37:1169-1173.
5. Arora NK, McHorney CA. Patient preferences for medical derision making who really wants to participate? Med Care 2000;38:335-341.
6. Nelson AA, Gagnon JP. Saliency of price in the acceptance of a chemically equivalent drug on a prescription. Medical Marketing Media 1974;9:17-31.
7. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharmaceut Assoc 2000;40:378-383.
8. Tootelian DH, Gaedeke RM, Schlacter J. Branded versus generic prescription drugs: Perceptions of risk, efficacy, safety and value. J Health Care Marketing 1988;8:26-29.
9. Momani A, Odedina F, Rosenbluth S, et al. Drug-management strategies: Consumers' perspectives. J Managed Care Pharmacy 2000;6:122-128.
10. Smith DG. The effects of repayments and generic substitution on the use and costs of prescription drugs. Inquiry 1993;30:189-198.
11. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Managed Care.1999;5:1383-1394.
12. Anis AH. Substitution laws, insurance coverage and generic drug use. Med Care 1994;32:240-256.
13. Gaither CA, Kirking DM, Ascione FJ, et al. Consumers' views on generic medications. J Am Pharmaceut Assoc 2001;41:729-736.
14. Kravitz RL, Bell RA, Franz CE, et al. Characterizing patient requests and physician responses in office practice. Health Services Res 2002;37:217-238.
15. Motheral B, Faiman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001;39:1293-1304.
16. Condra LJ, Morreale AP, Stolley SN, et al. Assessment of patient satisfaction with a formulary switch from omperazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Managed Care 1999;5:631-638.
17. Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Int Med 2000;160:2491-2496.
18. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin converting enzyme inhibitors. N Engl J Med 2002;346:822-829.
19. Hutchison S. Patient adherence to drug therapy in a three-tier copayment structure [abstract]. Value Health 2001;4:176.